Diabetes mellitus y riesgo cardiovascular: recomendaciones del Grupo de Trabajo Diabetes y Enfermedad Cardiovascular de la Sociedad Española de Diabetes (SED, 2015) / Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED, 2015)

El presente documento actualiza las recomendaciones de práctica clínica del manejo de los factores de riesgo cardiovascular (FRCV) en la diabetes mellitus (DM). Es un consenso médico realizado por un panel de expertos independiente de la Sociedad Española de Diabetes (SED). Se han propuesto y actualizado varios consensos de diferentes sociedades científicas o médicas con el fin de mejorar los resultados terapéuticos. La valoración del RCV en la población general puede carecer de sensibilidad para la evaluación individual en determinados grupos de riesgo como los diabéticos. Se revisan los factores de riesgo tradicionales y no tradicionales, así como las estrategias de intervención para el control de los FRCV en los pacientes diabéticos como la dieta, el control ponderal, el ejercicio físico, los hábitos tóxicos, el control glucémico, tensional y lipídico, así como la antiagregación plaquetaria. Confiamos en que estas pautas ayuden a los médicos en la toma de decisiones en su actividad asistencial. Se expone una actualización de los conceptos más relevantes y de mayor interés clínico-práctico y, a su vez realista, para reducir el RCV de los diabéticos como se venía haciendo regularmente por parte del Grupo de Enfermedad Cardiovascular de la SED

The present paper updates the Clinical Practice Recommendations for the management of cardiovascular risk factors (CVRF) in diabetes mellitus. This is a medical consensus agreed by an independent panel of experts from the Spanish Society of Diabetes (SED). Several consensuses have been proposed by scientific and medical Societies to achieve clinical goals. However, the risk score for general population may lack sensitivity for individual assessment or for particular groups at risk, such as diabetics. Traditional risk factors together with non-traditional factors are reviewed throughout this paper. Intervention strategies for managing CVRF in the diabetic patient are reviewed in detail: balanced food intake, weight reduction, physical exercise, smoking cessation, reduction in HbA1c, therapy for high blood pressure, obesity, lipid disorders, and platelet anti-aggregation. It is hoped that these guidelines can help clinicians in the decisions of their clinical activity. This regular update by the SED Cardiovascular Disease Group of the most relevant concepts, and of greater practical and realistic clinical interest, is presented in order to reduce CVR of diabetics

Comparative study between the Phramongkutklao's diabetic blenderized diets and commercial diabetic diets on glycemic variability in continuous tube fed patients with type 2 diabetes.

BACKGROUND: Rapid glucose fluctuations over daily period play an important role on diabetic complications. OBJECTIVE: To compare glycemic variability, mean plasma glucose, number ofcapillary blood glucose tests, and cost between the Phramongkutklao's diabetic formula and commercial diabetic formula in continuous tube fed patients with stable condition in type 2 diabetes. MATERIAL AND METHOD: A cross-over design study was performed between October 2010 and February 2011 in the medical department in Phramongkutklao Hospital. The researchers enrolled type 2 diabetic patients with stable condition who were on continuous tube fed. Seventy-two-hour continuous subcutaneous glucose monitoring was performed in all patients. Comparison ofmean amplitude ofglycemic excursions (MAGE), mean plasma glucose, cost, and number of capillary blood glucose tests were analyzed by using non-parametric Wilcoxon signed-rank test. Significance was defined as p<0.05. Results: Ten subjects were included in the present study. The Phramongkutklao's Diabetic Formula resulted in significantly lower mean plasma glucose (122±26.25 vs. 144.68±36.91 mg/dL, p = 0.022), cost (550.1±33.57 vs. 797.81±42.29 baht, p = 0.004), and number of capillary blood glucose tests (5±0.94 vs. 5.3±0.82 times, p = 0.083) when compared with commercial diabetic formula, but no significant difference in MAGE level (5.86±2.78 vs. 7.71±4.34 mg/dL, p = 0.333). CONCLUSION: The Phramongkutklao's diabetic formula has significantly lower mean plasma glucose, less number of capillary blood glucose tests, and is less expensive than commercial diabetic formula. The glucose variability (MAGE) of the Phramongkutklao diabetic formula has also less than commercial diabetic formula, but does not reach statistical significance. The level ofplasma glucose was lower than 180 mg/dL in both formulas.

Diet and diabetes in the Caribbean

The problem is that in many Caribbean countries, especially Trinidad and Tobago, Barbados and the Bahamas, an incipient scourge has developed. Referred to sometimes as "sugar" or "sweet blood", diabetes is our most expensive disease and the one responsible for the most deaths. Diabetes has everything to do with the way we eat and live. Statistics for Trinidad, which are most up to date, show that we need not look far to find someone with diabetes. One- but possibly as many as two- out of every ten people have it. These days it's a cultural problem. Sadly, even the very cuisine on which we pride ourselves has become a source of health problems. That together with two much 'liming', social drinking, and smoking are now all on a national bad list. So, now it is time we weigh the benifits of our lifestyle against its consequences.

Treatment of type 2 diabetes mellitus.

Although most patients with type 2 diabetes mellitus can be initially managed with diet and exercise alone, most eventually require at least oral agents if not insulin to maintain glycemic control. Appropriate therapeutic regimens may be difficult to design, given the diversity of drugs available for clinical use. Physicians must consider not only glycemic control, but also patient preference, concomitant medical conditions, and cost when designing therapeutic regimens.